StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)

Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –

Royalty Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Royalty Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $238.64M, down 32.2% year over year. For fiscal 2025 it was $452.00M, up 22500.0% from the year before. The highest annual figure on record is $452.00M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$452.00M+22500.0%
FY2024Dec 31, 2024$2.00M-96.2%
FY2023Dec 31, 2023$52.00M-70.6%
FY2022Dec 31, 2022$177.11M-11.5%
FY2021Dec 31, 2021$200.08M+661.1%
FY2020Dec 31, 2020$26.29M-68.3%
FY2019Dec 31, 2019$83.04M-78.9%
FY2018Dec 31, 2018$392.61M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$97.85M-67.4%
Q1 FY2026Mar 31, 2026$39.79M-21.2%
Q4 FY2025Dec 31, 2025$50.50M+10000.0%
Q3 FY2025Sep 30, 2025$50.50M+10000.0%
Q2 FY2025Jun 30, 2025$300.50M+60000.0%
Q1 FY2025Mar 31, 2025$50.50M+10000.0%
Q4 FY2024Dec 31, 2024$500.00K0.0%
Q3 FY2024Sep 30, 2024$500.00K-99.0%
Q2 FY2024Jun 30, 2024$500.00K0.0%
Q1 FY2024Mar 31, 2024$500.00K0.0%
Q4 FY2023Dec 31, 2023$500.00K-99.0%
Q3 FY2023Sep 30, 2023$50.50M+98.0%
Q2 FY2023Jun 30, 2023$500.00K-17.5%
Q1 FY2023Mar 31, 2023$500.00K-99.5%
Q4 FY2022Dec 31, 2022$50.50M-51.4%
Q3 FY2022Sep 30, 2022$25.50M-71.8%
Q2 FY2022Jun 30, 2022$606.00K-80.6%
Q1 FY2022Mar 31, 2022$100.50M+3705.4%
Q4 FY2021Dec 31, 2021$103.82M+1234.6%
Q3 FY2021Sep 30, 2021$90.50M+1675.9%
Q2 FY2021Jun 30, 2021$3.12M-45.9%
Q1 FY2021Mar 31, 2021$2.64M-65.4%
Q4 FY2020Dec 31, 2020$7.78M-51.0%
Q3 FY2020Sep 30, 2020$5.10M-77.6%
Q2 FY2020Jun 30, 2020$5.78M-73.1%
Q1 FY2020Mar 31, 2020$7.64M–
Q4 FY2019Dec 31, 2019$15.87M–
Q3 FY2019Sep 30, 2019$22.72M–
Q2 FY2019Jun 30, 2019$21.46M–

More Royalty Pharma figures

See a number that looks wrong?